| Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib D Marin, A Bazeos, FX Mahon, L Eliasson, D Milojkovic, M Bua, ... Journal of clinical oncology 28 (14), 2381, 2010 | 1121 | 2010 |
| Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis H De Lavallade, JF Apperley, JS Khorashad, D Milojkovic, AG Reid, ... Journal of Clinical Oncology 26 (20), 3358-3363, 2008 | 711 | 2008 |
| European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor D Marin, D Milojkovic, E Olavarria, JS Khorashad, H De Lavallade, ... Blood, The Journal of the American Society of Hematology 112 (12), 4437-4444, 2008 | 410 | 2008 |
| Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy AR Ibrahim, L Eliasson, JF Apperley, D Milojkovic, M Bua, R Szydlo, ... Blood, The Journal of the American Society of Hematology 117 (14), 3733-3736, 2011 | 392 | 2011 |
| BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia MS Zabriskie, CA Eide, SK Tantravahi, NA Vellore, J Estrada, FE Nicolini, ... Cancer cell 26 (3), 428-442, 2014 | 345 | 2014 |
| BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships JS Khorashad, TW Kelley, P Szankasi, CC Mason, S Soverini, LT Adrian, ... Blood, The Journal of the American Society of Hematology 121 (3), 489-498, 2013 | 254 | 2013 |
| The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib JS Khorashad, M Anand, D Marin, S Saunders, T Al-Jabary, A Iqbal, ... Leukemia 20 (4), 658-663, 2006 | 198 | 2006 |
| Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression JS Khorashad, H De Lavallade, JF Apperley, D Milojkovic, AG Reid, ... Journal of clinical oncology 26 (29), 4806, 2008 | 197 | 2008 |
| Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune‐mediated pathogenesis H De Lavallade, S Punnialingam, D Milojkovic, M Bua, JS Khorashad, ... British journal of haematology 141 (5), 745-747, 2008 | 184 | 2008 |
| Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia D Milojkovic, E Nicholson, JF Apperley, TL Holyoake, P Shepherd, ... haematologica 95 (2), 224, 2010 | 157 | 2010 |
| Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define … J Kaeda, D O'shea, RM Szydlo, E Olavarria, F Dazzi, D Marin, S Saunders, ... Blood 107 (10), 4171-4176, 2006 | 154 | 2006 |
| Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia AM Eiring, BDG Page, IL Kraft, CC Mason, NA Vellore, D Resetca, ... Leukemia 29 (3), 586-597, 2015 | 144 | 2015 |
| Age-related mutations and chronic myelomonocytic leukemia CC Mason, JS Khorashad, SK Tantravahi, TW Kelley, MS Zabriskie, ... Leukemia 30 (4), 906-913, 2016 | 143 | 2016 |
| In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib JS Khorashad, D Milojkovic, P Mehta, M Anand, S Ghorashian, AG Reid, ... Blood, The Journal of the American Society of Hematology 111 (4), 2378-2381, 2008 | 99 | 2008 |
| Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy AR Ibrahim, C Paliompeis, M Bua, D Milojkovic, R Szydlo, JS Khorashad, ... Blood, The Journal of the American Society of Hematology 116 (25), 5497-5500, 2010 | 81 | 2010 |
| BCR‐ABL1 kinase domain mutations: Methodology and clinical evaluation M Alikian, G Gerrard, PG Subramanian, K Mudge, P Foskett, ... American journal of hematology 87 (3), 298-304, 2012 | 75 | 2012 |
| Advances in the treatment of chronic myeloid leukemia AM Eiring, JS Khorashad, K Morley, MW Deininger BMC medicine 9, 1-6, 2011 | 72 | 2011 |
| KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib D Marin, IH Gabriel, S Ahmad, L Foroni, H De Lavallade, R Clark, ... Leukemia 26 (2), 296-302, 2012 | 69 | 2012 |
| hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia A Bazeos, D Marin, AG Reid, G Gerrard, D Milojkovic, PC May, ... Leukemia 24 (6), 1243-1245, 2010 | 64 | 2010 |
| Interferon-α or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation H De Lavallade, JS Khorashad, HP Davis, D Milojkovic, JS Kaeda, ... Blood, The Journal of the American Society of Hematology 110 (7), 2779-2780, 2007 | 59 | 2007 |
